164 related articles for article (PubMed ID: 20339477)
1. JAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients.
Cavalcanti E; Gigante M; Mancini V; Battaglia M; Ditonno P; Capobianco C; Cincione RI; Selvaggi FP; Herr W; Storkus WJ; Gesualdo L; Ranieri E
J Biomed Biotechnol; 2010; 2010():935764. PubMed ID: 20339477
[TBL] [Abstract][Full Text] [Related]
2. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
3. miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction.
Gigante M; Pontrelli P; Herr W; Gigante M; D'Avenia M; Zaza G; Cavalcanti E; Accetturo M; Lucarelli G; Carrieri G; Battaglia M; Storkus WJ; Gesualdo L; Ranieri E
J Transl Med; 2016 Apr; 14():84. PubMed ID: 27063186
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
5. Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor.
Singer K; Kastenberger M; Gottfried E; Hammerschmied CG; Büttner M; Aigner M; Seliger B; Walter B; Schlösser H; Hartmann A; Andreesen R; Mackensen A; Kreutz M
Int J Cancer; 2011 May; 128(9):2085-95. PubMed ID: 20607826
[TBL] [Abstract][Full Text] [Related]
6. High DGK-α and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention.
Prinz PU; Mendler AN; Masouris I; Durner L; Oberneder R; Noessner E
J Immunol; 2012 Jun; 188(12):5990-6000. PubMed ID: 22573804
[TBL] [Abstract][Full Text] [Related]
7. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma.
Tatsumi T; Herrem CJ; Olson WC; Finke JH; Bukowski RM; Kinch MS; Ranieri E; Storkus WJ
Cancer Res; 2003 Aug; 63(15):4481-9. PubMed ID: 12907621
[TBL] [Abstract][Full Text] [Related]
8. CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression.
Dörrschuck A; Schmidt A; Schnürer E; Glückmann M; Albrecht C; Wölfel C; Lennerz V; Lifke A; Di Natale C; Ranieri E; Gesualdo L; Huber C; Karas M; Wölfel T; Herr W
Blood; 2004 Oct; 104(8):2591-9. PubMed ID: 15231579
[TBL] [Abstract][Full Text] [Related]
9. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD8O) costimulation.
Wang YC; Zhu L; McHugh R; Graham SD; Hillyer CD; Dillehay D; Sell KW; Selvaraj P
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):1-8. PubMed ID: 9147700
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
[TBL] [Abstract][Full Text] [Related]
11. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
Bernhard H; Jäger E; Maeurer MJ; Meyer zum Büschenfelde KH; Knuth A
Tissue Antigens; 1996 Jul; 48(1):22-31. PubMed ID: 8864171
[TBL] [Abstract][Full Text] [Related]
12. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma.
Bukur J; Rebmann V; Grosse-Wilde H; Luboldt H; Ruebben H; Drexler I; Sutter G; Huber C; Seliger B
Cancer Res; 2003 Jul; 63(14):4107-11. PubMed ID: 12874014
[TBL] [Abstract][Full Text] [Related]
13. Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas.
Kolenko V; Wang Q; Riedy MC; O'Shea J; Ritz J; Cathcart MK; Rayman P; Tubbs R; Edinger M; Novick A; Bukowski R; Finke J
J Immunol; 1997 Sep; 159(6):3057-67. PubMed ID: 9300731
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
15. Dihydrotestosterone promotes kidney cancer cell proliferation by activating the STAT5 pathway via androgen and glucocorticoid receptors.
Pak S; Kim W; Kim Y; Song C; Ahn H
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2293-2301. PubMed ID: 31401673
[TBL] [Abstract][Full Text] [Related]
16. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
[TBL] [Abstract][Full Text] [Related]
17. Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones.
Bernhard H; Karbach J; Wölfel T; Busch P; Störkel S; Stöckle M; Wölfel C; Seliger B; Huber C; Meyer zum Büschenfelde KH
Int J Cancer; 1994 Dec; 59(6):837-42. PubMed ID: 7989126
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation.
Quandt D; Jasinski-Bergner S; Müller U; Schulze B; Seliger B
J Transl Med; 2014 May; 12():151. PubMed ID: 24885059
[TBL] [Abstract][Full Text] [Related]
19. CD8+ T cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and, combined with GM‑CSF and IL‑12, enhance the anti‑renal cortical adenocarcinoma effect.
Xu HY; Li N; Yao N; Xu XF; Wang HX; Liu XY; Zhang Y
Oncol Rep; 2019 Aug; 42(2):866-879. PubMed ID: 31233203
[TBL] [Abstract][Full Text] [Related]
20. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection.
MacFarlane AW; Jillab M; Plimack ER; Hudes GR; Uzzo RG; Litwin S; Dulaimi E; Al-Saleem T; Campbell KS
Cancer Immunol Res; 2014 Apr; 2(4):320-31. PubMed ID: 24764579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]